Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of TS-152 (Ozoralizumab) in Rheumatoid Arthritis
NCT04077567Phase 3Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 3 trial of ozoralizumab in rheumatoid arthritis (RA), sponsored by Taisho Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04077567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077567.